Treatment of steroid-resistant nephrotic syndrome with integrative traditional Chinese and western medicine

doi:10.3877/cma.j.issn.2095-3216.2015.04.003

Abstract

Abstract:

Steroid-resistant nephrotic syndrome (SRNS) is one of the common difficult kidney diseases in clinical practice, and belongs to intractable nephrotic syndrome. A growing number of scholars have been exploring treatment with integrative traditional Chinese and western medicine so as to improve clinical efficacy and ease the side effects from long-term use of high-dose immunosuppressants. In this article, the author systematically described steroid-resistance mechanism and factors affecting the effect of the steroid, and proposed to pay attention to standardized treatment. The following methods are worth using for reference in treatment of SRNS, including combination of tripterygium wilfordii preparation as "disease" differentiation treatment of traditional Chinese medicine with individualized dialectical treatment, combination of traditional syndrome differentiation and microcosmic syndrome differentiation, and combination of prescription selection with modern research results of traditional Chinese medicine.

Key words: Nephrotic syndrome, Steroid-resistance, Integrative Chinese and western medicine, Treatment

Ying Lu. Treatment of steroid-resistant nephrotic syndrome with integrative traditional Chinese and western medicine[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2015, 04(04): 177-181.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2015.04.003

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2015/V04/I04/177

References 21

[1]	Davin JC, Rutjes NW. Nephrotic syndrome in children: from bench to treatment [J]．Int J Nephrol, 2011, 10(8): 1-6.
[2]	周琼秀，陈楠. 成人激素抵抗性肾病综合征遗传学机制[J]. 肾脏病与透析肾移植杂志，2013，22(1)：70-74.
[3]	陈春梅，夏运成. 原发性肾病综合征激素抵抗的研究现状[J]．广东医学，2014, 35(3): 461-464.
[4]	王雪，耿龙，季永智，等. 糖皮质激素对其受体、热休克蛋白90和组蛋白去乙酰化酶6的影响及中药干预研究[J]. 中国医科大学学报，2010，39(8)：607-609.
[5]	Stachowskl J, Zanker CB, Runowski D, et al.Resistance to therapy in primary nephrotic syndrome: effect of MDR1 gene activity [J]．POL Merkuriusz Lek, 2000, 8(46): 218-221.
[6]	李世军，刘志红. 改善全球肾脏病预后组织(KDIGO)临床实践指南：肾小球肾炎[J]．肾脏病与透析肾移植杂志，2012，21(3)：260-267.
[7]	Kamburova EG, Koenen HJ, Borgman KJ，et al.A single dose of rituximab does not deplete B ceils in secondary lymphoid organs but alters phenotype and function [J]．Am J Transplant，2013，13(6)：1503-1511.
[8]	Audard V, Lang P, Sahali D. Minimal change nephrotic syndrome：new insights into disease pathogenesis [J]．Med Sci (Paris)，2008，24(10)：853-858.
[9]	Sinha A, Bagga A. Rituximab therapy in nephrotic syndrome: implications for patients′ management [J]. Nat Rev Nephrol, 2013, 9(3): 154-169.
[10]	Ito S, Kamei K, Ogura M，et al. Survey of rituximab treatment for childhood-onset refractory nephritic syndrome [J]. Pediatr Nephrol, 2013, 28(2): 257-264.
[11]	Gulati A, Sinha A, Jordan SC，et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report [J]. Clin J Am Soc Nephrol, 2010, 5(12): 2207-2212.
[12]	Prytula A, Iijima K, Kamei K, et al. Rituximab in refractory nephrotic syndrome [J]. Pediatr Nephrol, 2010, 25(3): 461-468.
[13]	Fernandez-Fresnedo G, Segarra A, González E，et al. Rituximab treatment of adult patients with steroid -resistant focal segmental glomerulosclerosis [J]. Clin J Am Soc Nephrol, 2009, 4(8): 1317-1323.
[14]	Bomback AS, Derebail VK, McGregor JG, et al. Rituximab therapy for membranous nephropathy: a systematic review [J]. Clin J Am Soc Nephrol, 2009, 4(4): 734-744.
[15]	Cravedi P, Sghirlanzoni MC, Marasà M, et al. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study [J]. Am J Nephrol, 2011, 33(5): 461-468.
[16]	Saran AM, Yuan H, Takeuchi E，et al.Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy [J]．Kidney Int，2003，64(6)：2072-2078.
[17]	Miwa T, Zhou L, Maldonado MA，et al.Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr mice [J]．J Immunol，2012, 189(11)：5434-5441.
[18]	Saleem MA. New developments in steroid-resistant nephrotic syndrome [J]. Pediatr Nephrol, 2013, 28(5): 699-709.
[19]	Hogan J, Mohan P, Appel GB. Diagnostic tests and treatment options in glomerular disease: 2014 update [J]. Am J Kidney Dis, 2014, 63(4): 656-666.
[20]	陈朝红，刘志红，孙骅，等．雷公藤甲素干预足细胞病变的体外观察[J]，肾脏病移植与透析杂志，2007，16(2)：119-126.
[21]	叶任高，孙升云．难治性肾病综合征探析[J]．新中医，2002，34(6)：3-5.

Please choose a citation manager

Content to export